RBC Capital raised the firm’s price target on Perspective Therapeutics (CATX) to $16 from $15 and keeps an Outperform rating on the shares. The company’s recent NET program data update at ASCO shows a competitive ORR – overall response rate – profile while maintaining best in class safety vs. comps even in the context of a small sample size, and the firm believes that profile can be maintained at the second-half update, enabling shares to inflect, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Promising Clinical Trial Results and Safety Profile Drive Buy Rating for Perspective Therapeutics
- Promising Clinical Updates and Strong Safety Profile Support Buy Rating for Perspective Therapeutics
- Perspective Therapeutics Reports Promising Trial Results for [212Pb]VMT-α-NET
- Perspective Therapeutics Holds Annual Stockholders Meeting
- Buy Rating on Perspective Therapeutics: Promising Clinical Data, Strategic Advancements, and Strong Financial Position